NCT07100873View on ClinicalTrials.gov

A Phase 1 Study of ADI-001 in Rheumatoid Arthritis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

March 30, 2027

Study Completion Date

March 30, 2028

Conditions
Rheumatoid Arthritis (RA)
Interventions
DRUG

ADI-001

Anti-CD20 CAR-T

DRUG

Fludarabine

Chemotherapy for Lymphodepletion

DRUG

Cyclophosphamide

Chemotherapy for Lymphodepletion

Trial Locations (1)

Unknown

Adicet Clinical Trials, Shanghai

Sponsors
All Listed Sponsors
lead

Adicet Therapeutics

INDUSTRY

NCT07100873 - A Phase 1 Study of ADI-001 in Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter